Also known as: formerly UCL-L1V
Tranzyme (Other)Ocera (Other)
Ocera will merge with Tranzyme's Terrapin Acquisition Inc. subsidiary in a stock deal to form a company called Ocera Therapeutics Inc.
UCL (Licensor)Ocera (Licensee)
UCL granted Ocera exclusive, worldwide rights to the university's UCL-L1V and all assets and technologies covering the use of the combination of L-ornithine and phenylbutyrate to treat acute hepatic encephalopathy (AHE)
Set Email Alert